Clinical Evaluation
As well as thousands of hours of testing, Axon’s effectiveness is backed by extensive clinical data. Three clinical trials involving 150 patients and 12,000 treatments have been conducted. This, combined with thousands of hours of additional testing, has generated billions of data points for analysis.
The results of the trials are conclusive – Axon is safe and effective.
Axon as a Pain Management System
Clinical studies of Axon have primarily focused on managing chronic pain. In these trials, patients rated their pain levels before and after treatment using a widely recognized 10-point scale.
A 2-point reduction on this scale is considered a significant improvement in pain intensity [1]. By analyzing the results of multiple trials, we found that Axon users, on average, experienced a 2-point decrease in their average pain intensity (from 5.6 to 3.6).
Furthermore, when considering both the worst and average pain levels, we observed a consistent 2-point reduction (from 6.3 to 4.3). Notably, 80% of trial participants reported an improvement in at least one pain rating.
Additional benefits of using the Axon system
As well as the pain ratings, patients were monitored to see if Axon affected other aspects of their lives, such as mental health (depression, anxiety, and stress), increased activity and sleep. Out of the eight different measures tracked, 97% of participants reported improvements in at least one or more of these areas while 70% saw improvements in mental health, anxiety, depression, and sleep.
These results suggest that the Axon system may have a multifaceted role in improving the overall well-being of people with chronic pain, addressing not only pain intensity but also related psychological and physiological factors. Observations show that, even when a patient’s pain scores may not have significantly improved, the positive impact on quality of life (through increased ability to engage in day to day activities, including returning to work) can be significant.
Aggregated Trial Data
The following graphs represent aggregated results across all trials where comparable data is available:
01.
Trial Results
Selected Trial Results
As well as thousands of hours of testing Axon has undergone three clinical trials with a total of 150 patients consisting of 12,000 treatments delivered and billions of lines of data analysed. The results of the trials are pretty conclusive, Axon is safe and effective with 94% of patients responding to treatment, 80% had a reduction in Pain and 65% had improvements in Mental Health, Anxiety and Depression as well as Sleep.
Below are some of the selected results from the trials:
Upcoming Auckland
Chronic Pain Trial
Auckland Trials
If you are interested in taking part in the Chronic Pain trial with the Waitemata District Health Board and live in the Upper North Island of New Zealand, then please contact the team.
For sales enquiries and trials outside Auckland
For all other trials and sales enquiries please contact the team at info@exsurgo.com.
Media
Chronic Pain Study (UK)
A recent UK study has confirmed the exciting potential of Exsurgo’s breakthrough treatment for chronic pain management.
In the UK study, conducted from mid-2020 until early 2021, patients reported significant reductions in their levels of pain, anxiety and depression. At the same time, they reported improvements in sleep, mood and quality of life. Furthermore, the improvements from the eight weeks of neurofeedback training were sustained at follow-up points – 4, 12 and 26 weeks. The full results of the trial are expected to be published shortly in a medical journal.
The UK study was intentionally small-scale, involving 16 patients, to serve as a proof-of-concept for the Axon system and lay the groundwork for further research. A much larger clinical trial is due to start in New Zealand shortly.
- Evaluation of Axon intervention on a large scale: Randomized Controlled Trial with 116 chronic pain patients in New Zealand.
- • Publication (The Journal of Pain, 2024) – https://www.jpain.org/article/s1526…
- Exploring Axon’s Potential in Neuropathic Pain Relief: A Pilot Study with 10 Neuropathic Pain Patients in Collaboration with UK NHS.
- • Publication (Archives of Rehabilitation Research and Clinical Translation, 2024) – https://www.archives-rrct.org/arti…
- Axon for the treatment of Chronic Migraine: A Mixed Methods Case Report.
- • Publication (Neuromodulation, 2023) – https://www.neuromodulationjourna…
- • Presented at the International Neuromodulation Society Conference, 2023 – https://www.researchgate.net/publ…
- Axon for the treatment of Neuropathic Pain: A Mixed Methods Case Report.
- • Presented at the Multidisciplinary Association for Spinal Cord Injury Professionals 25th Annual Conference, 2023 – https://www.researchgate.net/publ…
- Home-based Axon for Chronic Pain Management: Proof-of-Concept trial with 16 chronic pain patients in the UK.
- • Publication (Frontiers in Pain, 2022) – https://www.frontiersin.org/artic…
- Axon Intervention for Pain: A Case Study.
- • Presented at the International Association for the Study of Pain (IASP) Conference, 2021 – https://www.researchgate.net/publ…
- Axon neurofeedback altered brain activity and effectively reduced pain: A case series of Chronic Pain Patients.
- • Presented at the Neuromodulation Society of Australia and New Zealand (NSANZ) Conference, 2021 – https://www.researchgate.net/publ…
The information on this page was last updated September 2024
Read more >
Read more >
Read more >
Read more >
Read more >
Read more >
Read more >
Trial Publications:
UK POC Clinical Trial – Home-Based EEG Neurofeedback Intervention for the Management of Chronic Pain
116 Patient Home Based Axon intervention for Chronic Pain
Clinicial Trial in New Zealand – Home-based EEG neurofeedback for the treatment of chronic pain: A randomized controlled clinical trial
10 Patient Home Based Axon intervention for Chronic Pain